Hospitalization

WASHINGTON — A speaker at ASN Kidney Week provided what she called “a different perspective on hospitalization risk,” telling the audience that considering psychosocial factors may help with interventions aimed at reducing the risk of hospitalization for patients on hemodialysis.

PHILADELPHIA — Interventions with vitamin D or omega-3 failed to reduce rates of first heart failure hospitalization in a large cohort of healthy adults, although researchers observed a benefit for recurrent HF hospitalization with fish oil supplementation, according to findings from an ancillary study of the VITAL trial presented at the American Heart Association Scientific Sessions.

PHILADELPHIA — Sacubitril/valsartan reduced the risk for HF hospitalization more in women compared with men, and the overall benefit of sacubitril/valsartan was driven by a benefit in patients with chronic HF and a left ventricular ejection fraction below the normal range, according to two analyses of the PARAGON-HF trial of patients with HF with preserved EF presented at the American Heart Association Scientific Sessions.

Mortality and hospitalization risks are higher for adults with type 2 diabetes who experience larger fluctuations in HbA1c or have very high or very low average HbA1c levels, according to findings published in Diabetes Care.

Impaired mobility during hospitalization for acute MI may be a risk factor for functional decline among older patients who survived the event, according to a study published in JAMA Internal Medicine.

PARIS — Early intensive and sustained vasodilation was well tolerated among patients with acute HF, but it did not improve all-cause mortality and acute HF rehospitalizations at 180 days, according to data from the GALACTIC trial presented at the European Society of Cardiology Congress.

PHILADELPHIA — In a real-world population of patients hospitalized for HF with reduced ejection fraction, sacubitril/valsartan was associated with reduced risk for mortality and rehospitalization at 12 months, according to findings presented at the Heart Failure Society of America Scientific Meeting.

A person with type 2 diabetes is more likely to die in the 6 months after hospital admission if he or she lives in a disadvantaged neighborhood, whereas a person with type 1 diabetes of low socioeconomic status is more likely to be readmitted to the hospital within 28 days, according to study data presented at the European Association for the Study of Diabetes annual meeting.

For men with type 2 diabetes, the small increased risk for Fournier gangrene associated with SGLT-2 inhibitor treatment should not dissuade clinicians from prescribing them, according to a research letter published in JAMA Internal Medicine.

PARIS — In patients with HF with reduced ejection fraction and secondary mitral valve regurgitation, percutaneous mitral valve repair with MitraClip plus medical therapy offered no advantage over medical therapy alone for the outcomes of death and unplanned hospitalization for HF at 2 years.